These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 24372941)

  • 1. Real-world resource use and costs of adjuvant treatment for stage III colon cancer.
    van Gils CW; de Groot S; Tan SS; Redekop WK; Koopman M; Punt CJ; Uyl-de Groot CA
    Eur J Cancer Care (Engl); 2015 May; 24(3):321-32. PubMed ID: 24372941
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Capecitabine versus bolus fluorouracil plus leucovorin (folinic acid) as adjuvant chemotherapy for patients with Dukes' C colon cancer : economic evaluation in an Italian NHS setting.
    Di Costanzo F; Ravasio R; Sobrero A; Bertetto O; Vinante O; Luppi G; Labianca R; Amadori D; Barone C; Carlo Merlano M; Longo F; Mansueto G; Antonuzzo L; Gasperoni S
    Clin Drug Investig; 2008; 28(10):645-55. PubMed ID: 18783303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of adjuvant FOLFOX therapy for stage III colon cancer in Japan based on the MOSAIC trial.
    Shiroiwa T; Takeuchi T; Fukuda T; Shimozuma K; Ohashi Y
    Value Health; 2012; 15(2):255-60. PubMed ID: 22433756
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacoeconomic analysis of capecitabine versus 5-fluorouracil/leucovorin as adjuvant therapy for stage III colon cancer in Taiwan.
    Hsu TC; Chen HH; Yang MC; Wang HM; Chuang JH; Jao SW; Chiang HC; Wen CY; Tseng JH; Chen LT
    Value Health; 2011; 14(5):647-51. PubMed ID: 21839401
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant chemotherapy for colon cancer--analysis of treatment costs from the perspective of statutory sickness funds.
    Görner M; Riemer-Hommel P
    Z Gastroenterol; 2008 Jul; 46(7):681-8. PubMed ID: 18618379
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population-Based Cost-Minimization Analysis of CAPOX Versus Modified FOLFOX6 in the Adjuvant Treatment of Stage III Colon Cancer.
    Ho MY; Chang AY; Ruan JY; Cheung WY
    Clin Colorectal Cancer; 2016 Jun; 15(2):158-63. PubMed ID: 26524925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-utility analysis of adjuvant chemotherapy in patients with stage III colon cancer in Thailand.
    Lerdkiattikorn P; Chaikledkaew U; Lausoontornsiri W; Chindavijak S; Khuhaprema T; Tantai N; Teerawattananon Y
    Expert Rev Pharmacoecon Outcomes Res; 2015; 15(4):687-700. PubMed ID: 25327502
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness analysis of oxaliplatin compared with 5-fluorouracil/leucovorin in adjuvant treatment of stage III colon cancer in the US.
    Aballéa S; Chancellor JV; Raikou M; Drummond MF; Weinstein MC; Jourdan S; Bridgewater J
    Cancer; 2007 Mar; 109(6):1082-9. PubMed ID: 17265519
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world health care costs of relapsed/refractory multiple myeloma during the era of novel cancer agents.
    Gaultney JG; Franken MG; Tan SS; Redekop WK; Huijgens PC; Sonneveld P; Uyl-de Groot CA
    J Clin Pharm Ther; 2013 Feb; 38(1):41-7. PubMed ID: 23126374
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Economic impact of alternative adjuvant chemotherapy regimens for stage III colon cancer.
    Goerner M; Riemer-Hommel P
    Onkologie; 2009 Nov; 32(11):647-52. PubMed ID: 19887868
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-Effectiveness Analysis of Adjuvant Stage III Colon Cancer Treatment at Veterans Affairs Medical Centers.
    Soni A; Aspinall SL; Zhao X; Good CB; Cunningham FE; Chatta G; Passero V; Smith KJ
    Oncol Res; 2014; 22(5-6):311-9. PubMed ID: 26629943
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Time trends in chemotherapy (administration and costs) and relative survival in stage III colon cancer patients - a large population-based study from 1990 to 2008.
    van den Broek CB; Bastiaannet E; Dekker JW; Portielje JE; de Craen AJ; Elferink MA; van de Velde CJ; Liefers GJ; Kapiteijn E
    Acta Oncol; 2013 Jun; 52(5):941-9. PubMed ID: 23145507
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Redefining adjuvant chemotherapy in patients with stage III colon cancer: X-ACT trial.
    Glen H; Cassidy J
    Expert Rev Anticancer Ther; 2008 Apr; 8(4):547-51. PubMed ID: 18402521
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness analysis of bevacizumab combined with chemotherapy for the treatment of metastatic colorectal cancer in Japan.
    Shiroiwa T; Fukuda T; Tsutani K
    Clin Ther; 2007 Oct; 29(10):2256-67. PubMed ID: 18042483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Xeloda in Adjuvant Colon Cancer Therapy (X-ACT) trial: overview of efficacy, safety, and cost-effectiveness.
    Twelves CJ
    Clin Colorectal Cancer; 2006 Nov; 6(4):278-87. PubMed ID: 17241512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of rituximab as maintenance treatment for relapsed follicular lymphoma: results of a population-based study.
    Blommestein HM; Issa DE; Pompen M; Ten Hoor G; Hogendoorn M; Joosten P; Zweegman S; Huijgens PC; Uyl-de Groot CA
    Eur J Haematol; 2014; 92(5):398-406. PubMed ID: 24400940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CAPOX associated with toxicities of higher grade but improved disease-free survival when compared with FOLFOX in the adjuvant treatment of stage III colon cancer.
    Loree JM; Mulder KE; Ghosh S; Spratlin JL
    Clin Colorectal Cancer; 2014 Sep; 13(3):172-7. PubMed ID: 24630275
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-Effectiveness of Adjuvant Chemotherapy in the Treatment of Early-Stage Colon Cancer.
    Soni A; Chu E
    Clin Colorectal Cancer; 2015 Dec; 14(4):219-26. PubMed ID: 26072443
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative effectiveness of different chemotherapeutic regimens on survival of people aged 66 and older with stage III colon cancer: a "real world" analysis using Surveillance, Epidemiology, and End Results-Medicare data.
    Hsiao FY; Mullins CD; Onukwugha E; Pandya N; Hanna N
    J Am Geriatr Soc; 2011 Sep; 59(9):1717-23. PubMed ID: 21831168
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost analysis of adjuvant therapy with XELOX or FOLFOX4 for colon cancer.
    Xie Q; Wen F; Wei YQ; Deng HX; Li Q
    Colorectal Dis; 2013 Aug; 15(8):958-62. PubMed ID: 23506229
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.